Disc Medicine submits NDA for bitopertin in erythropoietic porphyria
PositiveFinancial Markets

Disc Medicine has submitted a New Drug Application (NDA) for bitopertin, a promising treatment for erythropoietic porphyria, a rare and debilitating condition. This submission is a significant step forward in addressing the unmet medical needs of patients suffering from this disorder, potentially offering them a new avenue for relief and improved quality of life.
— Curated by the World Pulse Now AI Editorial System